2024

• Messina, N., Croda, M., Dalcolmo, M., de Almeida e Val, F., de Oliveira, R., Dos Santos, G., Douglas, M., Gardiner, K., Gwee, A., Jardim, B., et al (2024). BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial. Journal of Infection, 89(4), 106245. [More Information]
• Tang, Y., Jiang, X., Zhu, C., Audsley, J., Tangkijvanich, P., Avihingsanon, A., Song, S., Liu, S., Lewin, S., George, J., Douglas, M., et al (2024). Circulating capsid-antibody-complexes (CACs) drive intrahepatic complement deposition and inform subclinical liver inflammation in chronic hepatitis B. Antiviral Research, 231, 106017. [More Information]
• Tu, T., Eslam, M., Berg, T., Chan, H., George, J., Douglas, M., Ajoyan, H., Nur Umami, R., Veeraraghavan, V., Boldbaatar, D., et al (2024). Inhibition of Cellular Factor TM6SF2 Suppresses Secretion Pathways of Hepatitis B, Hepatitis C, and Hepatitis D Viruses. The Journal of Infectious Diseases, 230(4), 970-981. [More Information]

2023

• Pittet, L., Moore, C., McDonald, E., Barry, S., Bonten, M., Campbell, J., Croda, J., Dalcolmo, M., Davidson, A., Douglas, M., Wood, N., et al (2023). Bacillus Calmette-Guérin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial. EClinicalMedicine, 64. [More Information]
• Rauff, B., Ramezani-Moghadam, M., Tay, E., George, J., Douglas, M. (2023). Development of an in vitro model to study hepatitis C virus-induced fibrosis. Future Virology, 18(12), 757-766. [More Information]
• Abomughaid, M., Tay, E., Pickford, R., Malladi, C., Read, S., Coorssen, J., Gloss, B., George, J., Douglas, M. (2023). PEMT Mediates Hepatitis C Virus-Induced Steatosis, Explains Genotype-Specific Phenotypes and Supports Virus Replication. International Journal of Molecular Sciences, 24(10). [More Information]
• El-Khobar, K., Tay, E., Diefenbach, E., Gloss, B., George, J., Douglas, M. (2023). Polo-like kinase-1 mediates hepatitis C virus-induced cell migration, a drug target for liver cancer. Life Science Alliance, 6(11). [More Information]

2022

• Howe, A., Rodrigo, C., Cunningham, E., Douglas, M., Dietz, J., Grebely, J., Popping, S., Sfalcin, J., Parczewski, M., Sarrazin, C., et al (2022). Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Reports, 4(5), 100462. [More Information]
• Jefferies, M., Rashid, H., Graham, R., Read, S., Banik, G., Lam, T., Njiomegnie, G., Eslam, M., Zhao, X., Ahmed, N., Douglas, M., George, J. (2022). COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out. Vaccines, 10(6). [More Information]
• Tu, T., Zehnder, B., Wettengel, J., Zhang, H., Coulter, S., Ho, V., Douglas, M., Protzer, U., George, J., Urban, S. (2022). Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells. JHEP Reports, 4(9). [More Information]

2021

• Wijaya, R., Read, S., Schibeci, S., Han, S., Azardaryany, M., van der Poorten, D., Lin, R., Yuen, L., Lam, V., Douglas, M., George, J., Ahlenstiel, G. (2021). Expansion of dysfunctional CD56-CD16+ NK cells in chronic hepatitis B patients. Liver International, 41(5), 969-981. [More Information]
• Wijaya, R., Read, S., Truong, N., Han, S., Chen, D., Shahidipour, H., Fewings, N., Schibeci, S., Azardaryany, M., Parnell, G., Booth, D., van der Poorten, D., Lin, R., George, J., Douglas, M., Ahlenstiel, G. (2021). HBV vaccination and HBV infection induces HBV-specific natural killer cell memory. Gut, 70(2), 357-369. [More Information]
• Wijaya, R., Read, S., Selvamani, S., Schibeci, S., Azardaryany, M., Ong, A., van der Poorten, D., Lin, R., Douglas, M., George, J., Ahlenstiel, G. (2021). Hepatitis C Virus (HCV) Eradication With Interferon-Free Direct-Acting Antiviral-Based Therapy Results in KLRG1+ HCV-Specific Memory Natural Killer Cells. The Journal of Infectious Diseases, 223(7), 1183-1195. [More Information]
• Howe, A., Ceccherini-Silberstein, F., Dietz, J., Popping, S., Grebely, J., Rodrigo, C., Lennerstrand, J., Douglas, M., Parczewsk, M., Harrigan, P., et al (2021). SHARED: An international collaboration to unravel hepatitis C resistance. Viruses, 13(8), 1580. [More Information]
• Liu, Y., Veeraraghavan, V., Pinkerton, M., Fu, J., Douglas, M., George, J., Tu, T. (2021). Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and Recurrence. Frontiers in Microbiology, 12, 665201. [More Information]

2020

• Zhand, S., Jazi, M., Mohammadi, S., Rasekhi, R., Rostamian, G., Kalani, M., Rostamian, A., George, J., Douglas, M. (2020). Covid-19: The immune responses and clinical therapy candidates. International Journal of Molecular Sciences, 21(15), 1-34. [More Information]
• Fan, J., Liu, X., Pan, W., Douglas, M., Bao, S. (2020). Epidemiology of coronavirus disease in Gansu Province, China, 2020. Emerging Infectious Diseases, 26(6), 1257-1265. [More Information]
• Tu, T., Douglas, M. (2020). Hepatitis B Virus Infection: From Diagnostics to Treatments. Viruses, 12(12), 1366. [More Information]
• Douglas, M., Tay, E., Wang, D., Ong, A., Wilson, C., Phu, A., Kok, J., Dwyer, D., Bull, R., Lloyd, A., George, J., et al (2020). Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance. Hepatology Communications, 4(6), 904-915. [More Information]
• Tu, T., Block, J., Wang, S., Cohen, C., Douglas, M. (2020). The lived experience of chronic hepatitis B: A broader view of its impacts and why we need a cure. Viruses, 12(5), 515. [More Information]

2019

• El Sharkawy, R., Bayoumi, A., Metwally, M., Mangia, A., Berg, T., Romero-Gomez, M., Abate, M., Irving, W., Sheridan, D., Dore, G., Latchoumanin, O., Thabet, K., Najim, M., Douglas, M., Liddle, C., Qiao, L., George, J., Eslam, M., et al (2019). A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms. Scientific Reports, 9(1), 1-10. [More Information]
• Douglas, M., Tay, E., Eden, J., George, J. (2019). Hepatitis C Virus Genotype 8 - successful treatment with sofosbuvir/velpatasvir. The Journal of Infectious Diseases, 220(4), 720-722. [More Information]
• Wijaya, R., Read, S., Schibeci, S., Eslam, M., Azardaryany, M., El-Khobar, K., van der Poorten, D., Lin, R., Yuen, L., Lam, V., George, J., Douglas, M., Ahlenstiel, G. (2019). KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B. Journal of Hepatology, 71(2), 252-264. [More Information]
• Read, S., Wijaya, R., Ramezani-Moghadam, M., Tay, E., Schibeci, S., Liddle, C., Lam, V., Yuen, L., Douglas, M., Booth, D., George, J., Ahlenstiel, G. (2019). Macrophage Coordination of the Interferon Lambda Immune Response. Frontiers in Immunology, 10, 1-16. [More Information]
• Ong, A., Tay, E., Dwyer, D., George, J., Douglas, M. (2019). Pre-treatment antiviral resistance in Australians with chronic hepatitis C: prevalence of NS3 and NS5A resistance data in the state of New South Wales. Antiviral Therapy, 24(4), 281-290. [More Information]

2018

• El Sharkawy, R., Thabet, K., Lampertico, P., Petta, S., Mangia, A., Berg, T., Metwally, M., Bayoumi, A., Douglas, M., Khan, A., et al (2018). A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 48(5), 564-573. [More Information]
• Sublette, V., Smith, S., George, J., McCaffery, K., Douglas, M. (2018). Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion. Journal of Health Psychology, 23(13), 1720-1731. [More Information]
• Laursen, T., Siggard, C., Kazankov, K., Sandahl, T., Moller, H., Ong, A., Douglas, M., George, J., Tarp, B., Kristensen, L., et al (2018). Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. Scandinavian Journal of Gastroenterology, 53(8), 986-993. [More Information]
• Read, S., Parnell, G., Booth, D., Douglas, M., George, J., Ahlenstiel, G. (2018). The antiviral role of zinc and metallothioneins in hepatitis C infection. Journal of Viral Hepatitis, 25(5), 491-501. [More Information]
• Patterson Ross, Z., Klunk, J., Fornaciari, G., Giuffra, V., Duchene, S., Duggan, A., Poinar, D., Douglas, M., Eden, J., Holmes, E., et al (2018). The paradox of HBV evolution as revealed from a 16th century mummy. PLoS Pathogens, 14(1), 1-25. [More Information]

2017

• Eslam, M., McLeod, D., Kelaeng, K., Mangia, A., Berg, T., Thabet, K., Irving, W., Dore, G., Sheridan, D., Gronbaek, H., Booth, D., Weltman, M., Douglas, M., Liddle, C., George, J., et al (2017). IFN-(lambda)3, not IFN-(lambda)4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nature Genetics, 49(5), 795-800. [More Information]
• Sublette, V., Smith, S., George, J., McCaffery, K., Douglas, M. (2017). Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion. Journal of Health Psychology, 22(10), 1300-1311. [More Information]
• Bartlett, S., Grebely, J., Eltahla, A., Reeves, J., Howe, A., Miller, V., Ceccherini-Silberstein, F., Bull, R., Douglas, M., Dore, G., et al (2017). Sequencing of Hepatitis C Virus for Detection of Resistance to Direct-Acting Antiviral Therapy: A Systematic Review. Hepatology Communications, 1(5), 379-390. [More Information]
• Read, S., O'Connor, K., Suppiah, V., Ahlenstiel, C., Obeid, S., Cook, K., Cunningham, A., Douglas, M., Hogg, P., Booth, D., George, J., Ahlenstiel, G. (2017). Zinc is a potent and specific inhibitor of IFN-(lambda)3 signaling. Nature Communications, 8, 1-15. [More Information]

2016

• Awan, Z., Tay, E., Eyre, N., Wu, L., Beard, M., Boo, I., Drummer, H., George, J., Douglas, M. (2016). Calsyntenin-1 mediates hepatitis C virus replication. Journal of General Virology, 97(8), 1877-1887. [More Information]
• Eslam, M., Mangia, A., Berg, T., Chan, H., Irving, W., Dore, G., Abate, M., Bugianesi, E., Adams, L., Najim, M., Weltman, M., Rahme, A., Booth, D., Liddle, C., Douglas, M., van der Poorten, D., George, J., White, R., Leung, R., et al (2016). Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology, 64(1), 34-46. [More Information]
• Eslam, M., Hashem, A., Romero-Gomez, M., Berg, T., Dore, G., Mangia, A., Chan, H., Irving, W., Sheridan, D., Abate, M., Weltman, M., Kelaeng, K., Ahlenstiel, G., Liddle, C., Douglas, M., Booth, D., George, J., et al (2016). FibroGENE: A gene-based model for staging liver fibrosis. Journal of Hepatology, 64(2), 390-398. [More Information]
• O'Connor, K., Read, S., Wang, X., Schibeci, S., Eslam, M., Ong, A., Weltman, M., Douglas, M., Mazzola, A., Craxi, A., Stewart, G., Liddle, C., George, J., Ahlenstiel, G., Booth, D., et al (2016). IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. Genes and Immunity, 17(6), 328-334. [More Information]
• Sheridan, D., Hajarizadeh, B., Fenwick, F., Matthews, G., Applegate, T., Douglas, M., Neely, D., Askew, B., Dore, G., George, J., et al (2016). Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection. Liver International, 36(12), 1774-1782. [More Information]
• Thabet, K., Asimakopoulos, A., Shojaei, M., Romero-Gomez, M., Mangia, A., Irving, W., Berg, T., Dore, G., Gronbaek, H., Sheridan, D., Weltman, M., White, R., Douglas, M., Liddle, C., van der Poorten, D., George, J., Eslam, M., et al (2016). MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nature Communications, 7, 1-8. [More Information]

2015

• Swaminathan, S., Dunckley, H., Ojaimi, S., Ling, M., Fulcher, D., Young, S., Kok, J., Douglas, M. (2015). Author reply: To PMID 25041771. Internal Medicine Journal, 45(2), 234-235. [More Information]
• Read, S., Tay, E., Shahidi, M., O'Connor, K., Booth, D., George, J., Douglas, M. (2015). Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response. PloS One, 10(8), 1-16. [More Information]
• Sublette, V., Hopwood, M., George, J., Smith, S., Perry, K., McCaffery, K., Douglas, M. (2015). Instrumental support to facilitate hepatitis C treatment adherence: Working around shortfalls in shared-care. Psychology, Health and Medicine, 20(2), 186-197. [More Information]
• Eslam, M., Hashem, A., Leung, R., Romero-Gomez, M., Berg, T., Dore, G., Chan, H., Irving, W., Sheridan, D., Abate, M., Weltman, M., Douglas, M., Liddle, C., Booth, D., George, J., Ahlenstiel, G., et al (2015). Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nature Communications, 6, 1-10. [More Information]
• Keighley, C., Hamor, P., Chen, S., Watts, M., Douglas, M., Kok, J., O'Sullivan, M., Mitchell, D., Packham, D., Sorrell, T., Iredell, J. (2015). Modern technology and infectious diseases activity data: how can we use this for service planning? Internal Medicine Journal, 45(6), 688-688. [More Information]
• Rauff, B., Douglas, M. (2015). Role of fibrogenic and inflammatory cytokines in HCV-induced fibrosis. Future Virology, 10(12), 1307-1319. [More Information]
• Sublette, V., Smith, S., George, J., McCaffery, K., Douglas, M. (2015). The Hepatitis C treatment experience: Patients' perceptions of the facilitators of and barriers to uptake, adherence and completion. Psychology & Health, 30(8), 987-1004. [More Information]
• Read, S., Tay, E., Shahidi, M., McLauchlan, J., George, J., Douglas, M. (2015). The Mechanism of Interferon Refractoriness During Hepatitis C Virus Infection and Its Reversal with a Peroxisome Proliferator-Activated Receptor [alpha] Agonist. Journal of Interferon and Cytokine Research, 35(6), 486-497. [More Information]

2014

• Douglas, M., Esmaili, S., George, J. (2014). A new role for IKK-alpha in Hepatitis C virus induced lipogenesis. Hepatology, 59(5), 2046-2049. [More Information]
• Beard, M., Ffrench, R., Gowans, E., Helbig, K., Eyre, N., Douglas, M., Grebely, J., Ahlenstiel, G., Locarnini, S., George, J., et al (2014). A Summary of the 20(th) International Symposium on Hepatitis C Virus and Related Viruses. Gastroenterology, 147(1), e1-e4. [More Information]
• Eltahla, A., Tay, E., Douglas, M., White, P. (2014). Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders. Antimicrobial Agents and Chemotherapy, 58(12), 7215-7224. [More Information]
• Shahidi, M., Tay, E., Read, S., Ramezani-Moghadam, M., Chayama, K., George, J., Douglas, M. (2014). Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents. Journal of General Virology, 95(11), 2468-2479. [More Information]
• Sivagnanam, S., van der Poorten, D., Douglas, M. (2014). Hepatic lesions and eosinophilia in an urban dweller. Liver International, 34(4), 643-643. [More Information]
• O'Connor, K., Parnell, G., Patrick, E., Ahlenstiel, G., Suppiah, V., van der Poorten, D., Read, S., Leung, R., Douglas, M., Yang, J., Stewart, G., Liddle, C., George, J., Booth, D. (2014). Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes and Immunity, 15(2), 88-94. [More Information]
• Read, S., Tay, E., Shahidi, M., George, J., Douglas, M. (2014). Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production. Journal of General Virology, 95(9), 1900-1910. [More Information]
• O'Connor, K., Ahlenstiel, G., Suppiah, V., Schibeci, S., Ong, A., Leung, R., van der Poorten, D., Douglas, M., Weltman, M., Stewart, G., Liddle, C., George, J., Booth, D. (2014). IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis. Innate Immunity, 20(6), 598-605. [More Information]
• Eslam, M., Leung, R., Romero-Gomez, M., Mangia, A., Irving, W., Sheridan, D., Spengler, U., Mollison, L., Cheng, W., Bugianesi, E., Douglas, M., Booth, D., George, J., Ahlenstiel, G., et al (2014). IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Journal of Hepatology, 61(2), 235-241. [More Information]
• Young, S., Ojaimi, S., Dunckley, H., Douglas, M., Kok, J., Fulcher, D., Lin, M., Swaminathan, S. (2014). Vancomycin-associated drug reaction with eosinophilia and systemic symptoms syndrome. Internal Medicine Journal, 44(7), 694-696. [More Information]
• Read, S., Douglas, M. (2014). Virus induced inflammation and cancer development. Cancer Letters, 345(2), 174-181. [More Information]

2013

• Fahrtash, F., Kariyawasam, V., Gray, T., Byth Wilson, K., George, J., Douglas, M. (2013). Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. World Journal of Gastroenterology, 19(5), 721-726. [More Information]
• Sublette, V., Douglas, M., McCaffery, K., George, J., Nicholson Perry, K. (2013). Psychological, lifestyle and social predictors of hepatitis c treatment response: a systematic review. Liver International, 33(6), 894-903. [More Information]

2012

• Read, S., Douglas, M. (2012). Hepatitis C Virus Genotypes. In Geoffrey W. McCaughan, John G. McHutchison, Jean-Michel Pawlotsky (Eds.), Advanced Therapy for Hepatitis C, (pp. 12-16). Chichester, United Kingdom: Wiley-Blackwell Publishing. [More Information]

2011

• Pattullo, V., Douglas, M., George, J. (2011). Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis? Expert Review of Gastroenterology and Hepatology, 5(2), 265-277. [More Information]

2010

• Nguyena, O., Sheppeard, V., Douglas, M., Tu, E., Rawlinson, W. (2010). Acute hepatitis C infection with evidence of heterosexual transmission. Journal Of Clinical Virology, 49(1), 65-68. [More Information]
• van der Poorten, D., Shahidi, M., Tay, E., Sesha, J., Tran, K., McLeod, D., Milliken, J., Ho, V., Hebbard, L., Douglas, M., George, J. (2010). Hepatitis C Virus Induces the Cannabinoid Receptor 1. PloS One, 5(9), 1-10. [More Information]
• Targett-Adams, P., Boulant, S., Douglas, M., McLauchlan, J. (2010). Lipid metabolism and HCV infection. Viruses, 2(5), 1195-1217. [More Information]

2009

• Douglas, M., George, J. (2009). Molecular mechanisms of insulin resistance in chronic hepatitis C. World Journal of Gastroenterology, 15(35). [More Information]

2008

• Boulant, S., Douglas, M., Moody, L., Budkowska, A., Targett-Adam, P., McLauchlan, J. (2008). Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner. Traffic, 9(8), 1268-1282. [More Information]
• Douglas, M. (2008). Retrograde Cellular Transport of Herpes Simplex Virus: Interactions between Viral and Motor Proteins - a Gene Therapy Vector for Spinal Cord Disease?. Germany: VDM Verlag Dr Muller.
• Diefenbach, R., Miranda Saksena, M., Douglas, M., Cunningham, A. (2008). Transport and egress of herpes simplex virus in neurons. Reviews in Medical Virology, 18(1), 35-51. [More Information]

2007

• Douglas, M., Stephens, D., Burrow, J., Anstey, N., Talbot, K., Currie, B. (2007). Murray Valley encephalitis in an adult traveller complicated by long-term flaccid paralysis: case report and review of the literature. Transactions of the Royal Society of Tropical Medicine and Hygiene, 101(3), 284-288. [More Information]

2006

• Cunningham, A., Diefenbach, R., Miranda Saksena, M., Bosnjak, L., Kim, M., Jones, C., Douglas, M. (2006). The cycle of human herpes simplex virus infection: virus transport and immune control. The Journal of Infectious Diseases, 194(Supplement 1), S11-S18. [More Information]

2005

• Vittone, V., Diefenbach, E., Triffett, D., Douglas, M., Cunningham, A., Diefenbach, R. (2005). Determination of interactions between tegument proteins of herpes simplex virus type 1. Journal of Virology, 79(15), 9566-71. [More Information]
• Swaminathan, A., Gosbell, I., Zwar, N., Douglas, M. (2005). Tungiasis in recently arrived African refugees. Medical Journal of Australia, 183(1), 51. [More Information]

2004

• Douglas, M., Lum, G., Roy, J., Fisher, D., Anstey, N., Currie, B. (2004). Epidemiology of community-acquired and nosocomial bloodstream infections in tropical Australia: a 12-month prospective study. Tropical Medicine and International Health, 9(7), 795-804. [More Information]
• Douglas, M., Diefenbach, R., Homa, F., Miranda Saksena, M., Rixon, F., Vittone, V., Byth Wilson, K., Cunningham, A. (2004). Herpes Simplex Virus Type 1 Capsid Protein Vp26 Interacts With Dynein Light Chains Rp3 And Tctex1 And Plays A Role In Retrograde Cellular Transport. Journal of Biological Chemistry, 279(27), 28522-28530. [More Information]
• Diefenbach, R., Diefenbach, E., Douglas, M., Cunningham, A. (2004). The Ribosome Receptor, P180, Interacts With Kinesin Heavy Chain, KIF5B. Biochemical and Biophysical Research Communications, 319(3), 987-992. [More Information]
• Douglas, M., Johnson, R., Cunningham, A. (2004). Tolerability of Treatments for Postherpetic Neuralgia. Drug Safety, 27(15), 1217-33. [More Information]

2003

• Douglas, M., Bradbury, R., Kannangara, S., Mitchell, D. (2003). Arthritis as an Unusual Manifestation of Kikuchi-Fujimoto Disease. Rheumatology (Print Edition), 42(8), 1010-1012. [More Information]
• Douglas, M., Fisher, D., Lum, G., Roy, J. (2003). Mycoplasma hominis Infection of a Subdural Haematoma in the Peripartum Period. Pathology, 35(5), 452-454. [More Information]

2002

• Douglas, M., Walters, J., Currie, B. (2002). Occupational infection with herpes simplex virus type 1 after a needlestick injury. Medical Journal of Australia, 176(5), 240. [More Information]
• Diefenbach, R., Diefenbach, E., Douglas, M., Cunningham, A. (2002). The Heavy Chain of Conventional Kinesin Interacts with the SNARE Proteins SNAP25 and SNAP23. Biochemistry, 41(50), 14906-14915. [More Information]

2001

• Douglas, M., Mulholland, K., Denyer, V., Gottlieb, T. (2001). Multi-drug resistant Pseudomonas aeruginosa outbreak in a burns unit - an infection control study. Burns, 27(2), 131-135.